¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primed lymphocyte typing"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® lymphocyte ÇÑ±Û ¸²ÇÁ±¸
¼³¸í   
  ¸é¿ª±â´ÉÀ» ´ã´çÇϴ ¼¼Æ÷. °ñ¼ö¿¡¼­ ¸¸µé¾îÁö¸ç, ¸²ÇÁ±¸´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷, B¸²ÇÁ¼¼Æ÷·Î ³ª´µ¾îÁö°Ô µÈ´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â(¸é¿ª¹ÝÀÀ 4¹øÇü µî) µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ°¨¿°¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ» ´ã´çÇÑ´Ù.
¿µ¹® T-lymphocyte ÇÑ±Û Æ¼ ¸²ÇÁ±¸
¼³¸í   
  ¸²ÇÁ°è¼¼Æ÷(¸²ÇÁ±¸)´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷(T-cell), B¸²ÇÁ¼¼Æ÷(B-cell)·Î ³ª´µ¾îÁø´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º ¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º ¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±â´ÉÀ» ´ã´çÇÑ´Ù. T-¸²ÇÁ±¸´Â ¸é¿ª±â´É¿¡ °¡Àå Áß¿äÇÑ ¿ªÇÒÀ» Çϴ ¼¼Æ÷·Î¼­ ¼¼Æ÷¸é¿ªÀ» ´ã´çÇϸç B-cellÀÇ ÀÛ¿ëÀ» Á¶ÀýÇϴ ±â´Éµµ ÀÖ´Ù. °ñ¼ö¿¡¼­ »ý¼ºµÇ¾î °¡½¿»ù¿¡¼­ ¼º¼÷µÈ´Ù. Å©°Ô º¸Á¶T¼¼Æ÷(helper T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» º¸Á¶ÇÑ´Ù)¿Í T¼¼Æ÷(suppressor T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» ¾ïÁ¦ÇÑ´Ù)·Î ±¸ºÐµÇ¸ç À̵éÀº ¼¼Æ÷ Ç¥¸é¿¡ ºÐÆ÷Çϴ Ç׿ø¿¡ ÀÇÇØ¼­ ½Äº°µÉ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte typing
    ÃÊȸ¹Î°¨¸²ÇÁ±¸Çü°áÁ¤
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
  • primed cell
    ÃÊȸ¹Î°¨¼¼Æ÷
  • ABO typing
    ABOÇ÷¾×Çü°Ë»ç
  • histocompatibility typing test
    Á¶Á÷ÀûÇÕ¼ºÀ¯Çü°Ë»ç
  • homozygous typing method
    µ¿Á¾Á¢ÇÕÇüº°ÆÇº°¹ý
  • atypical lymphocyte
    ºñÁ¤Çü¸²ÇÁ±¸
  • effector lymphocyte
    È¿°ú¸²ÇÁ±¸
  • killer lymphocyte
    »ìÇØ¸²ÇÁ±¸, ¼¼Æ÷µ¶¼º¸²ÇÁ±¸
  • lymphocyte
    ¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤ÀÎÀÚ
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • mixed lymphocyte culture test
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • lymphocyte
    ¸²ÇÁ±¸
  • typing
    Çü°áÁ¤
  • ABO typing
    ¿¡À̺ñ¿ÀÇ÷¾×Çü°Ë»ç
  • serum typing
    Ç÷ûÇü°Ë»ç
  • tissue typing
    Á¶Á÷Çü°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈĸ²ÇÁ±¸Çüº°È­
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte-typing test
    °¨ÀÛ¸²ÇÁ±¸Çüº°°Ë»ç
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
  • primed cell
    ÃÊȸ°¨ÀÛ¼¼Æ÷
  • ABO typing
    ¿¡À̺ñ¿ÀÇ÷¾×Çü°Ë»ç
  • bacteriophage typing
    ¹ÚÅ׸®¿ÀÆÄÁöÇüº°, ¹ÚÅ׸®¿ÀÆÄÁöÇü°áÁ¤
  • complement typing
    º¸Ã¼Çüº°°Ë»ç
  • homozygous typing method
    µ¿ÇüÁ¢ÇÕ¼ºÇüº°ÆÇº°¹ý
  • leukocyte typing
    ¹éÇ÷±¸Çü°áÁ¤
  • serum typing
    Ç÷ûÇü°Ë»ç
  • typing
    Çü°áÁ¤
  • tissue typing
    Á¶Á÷Çü°Ë»ç
  • atypical lymphocyte
    ºñÀüÇü¸²ÇÁ±¸
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤±â
  • effector lymphocyte
    ÀÛµ¿¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È­
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte-typing test
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸ÀÌ¿ë Çüº°°Ë»ç
  • primed lymphocyte
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
  • T cell ; T lymphocyte ; thymus derived lymphocyte
    T¼¼Æ÷ ; T¸²ÇÁ? ; Èä¼±À¯·¡¸²ÇÁ?
  • primed
    ÃÊȸ°¨ÀÛ[µÈ]
  • primed
    ÃÊȸÇ׿øÀÚ±Ø(ôøüÞù÷ê«ô§Ð½)À» ¹ÞÀº.
  • primed
    ÃÊȸÇ׿øÀÚ±Ø(ôøüÞù÷ê«í©Ð½)À» ¹ÞÀº
  • primed T cell
    ÃÊȸ°¨ÀÛ T¼¼Æ÷
  • ABO typing
    ABO ±³Â÷°Ë»ç
  • ABO typing
    ABO Çüº°<Ç÷¾×Çü>°Ë»ç
  • Griffiths typing
    ±×¸®Çǽº ¿¬¼â±¸±ÕÇüº°°Ë»ç¹ý
  • front typing
    µ¿°áÇØµ¿ÀûÇ÷±¸
  • homozygous typing method
    µ¿ÇüÁ¢ÇÕ¼º Çüº°ÆÇº°¹ý
  • phage typing
    ÆÄÁöÇü¹ú(¡­úþܬ).
  • phage typing
    ÆÄÁöÇüº°
  • B cell/lymphocyte
    B ¼¼Æ÷/¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È­
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte-typing test
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸ÀÌ¿ë Çüº°°Ë»ç
  • primed lymphocyte
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
  • cell, primed T
    ÃÊȸ°¨ÀÛ T¼¼Æ÷
  • leader RNA primed transcription
    ¼±µµ RNA ½Ã¹ßÀü»ç
  • primed
    ÃÊȸÇ׿øÀÚ±Ø(ôøüÞù÷ê«ô§Ð½)À» ¹ÞÀº.
  • primed
    ÃÊȸÇ׿øÀÚ±Ø(ôøüÞù÷ê«í©Ð½)À» ¹ÞÀº
  • primed
    ÃÊȸ°¨ÀÛ[µÈ]
  • primed T cell
    ÃÊȸ°¨ÀÛ T¼¼Æ÷
  • bacteriophage typing
    ¹ÚÅ׸®¿ÀÆÄÁöÇüº°¹ý
  • bacteriophage typing
    ¼¼±ÕÆÄ¾ÆÁöÇüº°È­(úþܬûù)
  • cell typing
    Ç÷±¸Çü°Ë»ç
  • complement typing
    º¸Ã¼Çüº°È­(úþܬûù)
  • front typing
    µ¿°áÇØµ¿ÀûÇ÷±¸
  • homozygous typing method
    µ¿ÇüÁ¢ÇÕ¼º Çüº°ÆÇº°¹ý
  • phage typing
    ÆÄÁöÇüº°
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Small lymphocyte
    ÀÛÀº¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ¼ÒÀӯı¸
  • Large lymphocyte
    Å«¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ´ëÀӯı¸
  • Medium-sized lymphocyte
    Áß°£¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ÁßÀӯı¸
  • Lymphocyte
    ¸²ÇÁ±¸
    [¿¾ ¿ë¾î] Àӯı¸
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • primed cell
    °¨ÀÛ¼¼Æ÷(ÊïíÂá¬øà)
  • primed synthesis method
    ±âÆø ÇÕ¼º¹ý(ÑÃøïùêà÷Ûö)
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸-À¯µµ(ë¯Óô) È­ÇÐÁÖ¼ºÀÎÀÚ(ûùùÊñËà÷ì×í­)
  • lymphocyte transformation
    ¸²ÇÁ±¸º¯Çü(ܨû¡)
  • mixed lymphocyte culture
    È¥ÇÕ(ûèùê)¸²ÆÄ±¸¹è¾ç(ÛÆå×)
  • small lymphocyte
    ¼Ò(á³)Àӯı¸
  • T lymphocyte
    T Àӯı¸
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte
    ¸²ÇÁ±¸
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • T lymphocyte
    T¸²ÇÁ±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PLT pancreatic lymphocytic infiltration; platelet; primed lymphocyte test; primed lymphocyte typing; psi...
PLT Primed Lymphocyte Typing
MORAC mixed oligonucleotides primed amplification of complementary deoxyribonucleic acid
BlT bleeding time; blood test; blood type, blood typing
BT base of tongue; bedtime; bitemporal; bitrochanteric; bladder tumor; Blalock-Taussig [shunt]; bleedin...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PLT Primed Lymphocyte Typing
PLT Primed Lymphocyte Test
HTC Homozygous Typing Cell
MLST Multi Locus Sequence Typing
SBT Sequence-based typing
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • primed
    ÃÊȸ Ç׿ø ÀÚ±ØÀ» ¹ÞÀº
    ÃÖÃÊÀÇ Ç׿ø ÀÚ±ØÀ» ¹ÞÀº °á°ú ¸é¿ªÇÐÀûÀ¸·Î Ȱ¼ºÈ­ÇÏ´Â. ¸é¿ª°èÀÇ ¼¼Æ÷¿¡ °üÇÏ¿© »ç¿ëµÇ´Â ¿ë¾î.
  • blood typing
    Ç÷¾×Çü ÆÇÁ¤
  • cell typing
    Ç÷±¸Çü °Ë»ç
  • HLA typing
    ÀÎü Àӯı¸ Ç׿ø Çüº°
  • phage typing
    ÆÄ¾ÆÁö Çü¹ú, ÆäÀÌÁö Çü
    ÆÄÁö¿¡ ´ëÇÑ °¨¼ö¼º À¯¹«¿¡ µû¶ó ¼¼±ÕÀ» ºÐ·ù, Çüº°ÇÏ´Â ¹æ¹ýÀ» ÆÄÁöÇüº°À̶ó°í ÇÑ´Ù. Àü¿° °æ·Î¸¦ Á¶»çÇÏ´Â µîÀÇ ¿ªÇÐÀû ¿¬±¸¿¡ ÀÌ¿ëµÇ°í ÀÖ´Ù. ÆÄÁö °¨¼ö¼ºÀ» Á¶»çÇÏ´Â °æ¿ì¿¡´Â ÀϹÝÀûÀ¸·Î ¼¼±ÕÀ» ÆòÆÇ ¹èÁö¿¡ ½É¾î ±× À§¿¡ Àû´ç ³óµµÀÇ ÆÄÁö¾×À» ÇÑ ¹æ¿ï ¶³¾î¶ß·Á ¹è¾çÇØ¼­, ±× ºÎºÐÀÇ ¿ë±ÕÀÇ À¯¹«¿¡ ÀÇÇØ¼­ ÆÇÁ¤ÇÑ´Ù. Æ÷µµ ±¸±ÕÀÇ ÆÄÁö Çüº°À» Àß È®¸³µÇ¾î ÀÖÀ¸¸ç ¿ë±ÕÀÇ ÆÐÅÏ¿¡ µû¶ó¼­ 1, 2, 3, 4 ¹× È¥ÇÕ±ºÀ¸·Î ºÐ·ùµÇ°í ÀÖ´Ù. Çüº° ºÒ´ÉÇÑ ±ÕÁÖµµ ÀÖ´Ù. ±× ¿Ü¿¡ À导ÇÁ½º±Õ, µðÇÁÅ׸®¾Æ±Õ, ·»¼­±¸±Õ, ÄÝ·¹¶ó±Õ, Ç×»ê±Õ µî¿¡ ´ëÇØ¼­µµ ½ÃµµµÇ°í ÀÖ´Ù.
  • B lymphocyte
    B ¸²ÇÁ±¸
    1. Èä¼± ºñÀÇÁ¸¼ºÀ¸·Î Èä¼±ÀÇ ¿µÇâÀ» ¹ÞÁö ¾Ê°í, Á¶Á÷À» À¯ÁÖÇÏ´Â ¸²ÇÁ±¸. ü¾×¼º ¸é¿ª¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Ç׿ø¿¡ ÀÇÇÑ ÀÚ±ØÀ¸·Î ¾×¼º Ç×ü¸¦ ÇÕ¼ºÇÏ´Â ÇüÁú±¸·Î µÈ´Ù. 2. Ç÷¾×, °ñ¼ö ¹× ¸²ÇÁÀý, ºñÀå, Æíµµ µî ¸²ÇÁÁ¶Á÷, ±×¸®°í ¼ÒÈ­°ü°è µîÀÇ ºñ¸²ÇÁ Á¶Á÷¿¡ ºÐÆ÷ÇÑ´Ù. ÀÎü Ç÷¾×ÀÇ 10-20% Â÷ÁöÇÑ´Ù. Ç׿ø µî¿¡ ÀÇÇØ Ȱ¼ºÈ­µÇ¸é ¸²ÇÁ¿©Æ÷ ³»¿¡¼­ ¸ð¼¼Æ÷ º¯È¯
  • B-lymphocyte
    B ¸²ÇÁ±¸
    Ç÷Áß Àӯı¸ÀÇ 5-15%¸¦ Â÷ÁöÇÏ¸ç ¼¼Æ÷ Ç¥¸é¿¡ ¸é¿ª ±Û·ÎºÎ¸°ÀÌ Á¸ÀçÇÑ´Ù. ÀÌµé ¸é¿ª ±Û·ÎºÎ¸°Àº Ç׿ø¿¡ ´ëÇÑ ¼ö¿ëü·Î ÀÛ¿ëÇÑ´Ù. Ç÷Áß B ¼¼Æ÷ÀÇ ´ëºÎºÐÀº Ç¥¸é¿¡ IgM°ú IgD¸¦ °®°í ÀÖÀ¸¸ç ¼Ò¼ö¿¡¼­ IgG, IgA ȤÀº IgE°¡ ¹ß°ßµÈ´Ù. ±×·¯³ª Á¡¸· µî¿¡¼­´Â IgA¸¦ °®°í ÀÖ´Â B¼¼Æ÷°¡ ¸¹ÀÌ ¹ß°ßµÈ´Ù.
  • bone marrow-derived lymphocyte
    °ñ¼ö À¯·¡ Àӯı¸
  • bursa-derived lymphocyte
    ÆÄºÎ¸®½Ã¿ì½º ³¶ À¯·¡ Àӯı¸
  • effector lymphocyte
    ÀÛµ¿ ¸²ÇÁ±¸
  • immunocompetent T lymphocyte
    ¸é¿ª Àû°Ý T Àӯı¸
  • lymphocyte
    Àӯı¸
  • lymphocyte defined antigen
    ¸²ÇÁ±¸ ±ÔÁ¤ Ç׿ø
  • lymphocyte migration
    Àӯı¸ À̵¿
  • marrow lymphocyte
    °ñ¼ö ¸²ÇÁ±¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
lymphocyte lymphocyte A type of non-granular antibodies.
(09 Oct 1997)
bacterial typing techniques Procedures for identifying types and strains of bacteria. The most frequently employed typing systems are bacteriophage typing and serotyping as well as bacteriocin typing and biotyping.
(12 Dec 1998)
bacteriophage typing A technique of bacterial typing which differentiates between bacteria or strains of bacteria by their susceptibility to one or more bacteriophages.
(12 Dec 1998)
phage typing <microbiology> Bacteria may be typed by their susceptibility to a range of bacteriophages though confusion may arise if the bacteria carry plasmids encoding restriction endonucleases.
(18 Nov 1997)
mycological typing techniques Procedures for identifying types and strains of fungi.
(12 Dec 1998)
HLA typing <immunology> Tests done in order to determine if a patient has antibodies against a potential donor's HLA antigens. The presence of antibodies means that a particular graft will be rapidly rejected.
(05 Mar 2000)
DNA typing <molecular biology> See restriction fragment length polymorphism.
(18 Nov 1997)
tissue typing <procedure> The process of determining the allelic types of the antigens of the major histocompatibility complex (MHC) that determine whether a tissue graft will be accepted or rejected. at present carried out either by use of polyclonal or monoclonal antibodies against MHC antigens or less usually by tests of MHC restricted cell function or skin grafting (the latter not in humans).
(18 Nov 1997)
typing Classification according to type.
Origin: see type
Bacteriophage typing, a microbiological procedure, of epidemiological importance, for distinguishing types within a seemingly homogeneous bacterial species or strain by the use of type-specific bacteriophage.
HLA typing, tests done in order to determine if a patient has antibodies against a potential donor's HLA antigens. The presence of antibodies means that a particular graft will be rapidly rejected. Also used to establish paternity and in forensic medicine.
(05 Mar 2000)
antigens, differentiation, b-lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumours of B-cell origin.
(12 Dec 1998)
antigens, differentiation, t-lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
(12 Dec 1998)
bare lymphocyte syndrome <syndrome> Absence of HLA antigens on peripheral mononuclear cells, which may result in immunodeficiency.
(05 Mar 2000)
B lymphocyte <haematology, immunology> An immunologically important lymphocyte, produced by the bone marrow, that is responsible for the production of immunoglobulins, it is the precursor of the plasma cell.
The surface markers can be used to detect and differentiate chronic lymphocytic leukaemia from acute lymphocytic leukaemia.
(13 Nov 1997)
b-lymphocyte subsets A classification of B-lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
gene rearrangement, b-lymphocyte Ordered rearrangement of b-lymphocyte variable gene regions coding for the immunoglobulin chains, thereby contributing to antibody diversity. It occurs during the differentiation of the immature b-lymphocyte.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte
    ¸²ÇÁÅç(¼¼Æ÷)
  • typing
    ŸÀÌÇÁ¸¦ Ä¡±â
  • typing
    ŸÀÌÇÁ¶óÀÌÇÁÄ¡±â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á